AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Hsp90 and Grp94 Inhibitors for the Treatment of Primary Open Angle Glaucoma

Technology Benefits

Promising diagnostic toolMay provide new opportunities for the treatment of additional diseases

Technology Application

therapeutic strategy for myocilin glaucoma

Detailed Technology Description

Our inventors have developed a novel strategy that holds considerable promise for treating myocilin glaucoma. Through selectively targeting the endoplasmic reticulum chaperone Grp94 using siRNA knockdown or small molecule inhibitors, mutant myocilin can be removed in an efficient manner. Additionally, analogous inhibition of the paralog Hsp90 is under investigation as a therapeutic approach for a variety of diseases including cancer and Alzheimer's disease. The potential benefits of this treatment offers a significant effort towards understanding and preventing this disease.

Country/Region

USA

For more information, please click Here